The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1628
ISSUE 1628
July 12, 2021
Issue 1628
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Aducanumab (Aduhelm) for Alzheimer's Disease
July 12, 2021 (Issue: 1628)
Aducanumab-avwa (Aduhelm – Biogen/Eisai), an
IV amyloid beta-directed monoclonal antibody,
has received accelerated approval from the FDA
for treatment of Alzheimer's disease. The approval
was based on the surrogate endpoint of reduction...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.